Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New obesity drug trial aims for 25% weight loss with gentler dosing

NCT ID NCT07639021

Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 17, 2026 · Updated 3 times

Summary

This study tests a new medicine called NNC0662-0419 in 230 adults with obesity (BMI 30 or higher). Researchers want to see if different ways of increasing the dose over time can reduce stomach side effects while still helping people lose at least 25% of their body weight. The study is not yet recruiting and is run by Novo Nordisk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

233 people

The number who actually took part.

Started

Jun 2026

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female (sex assigned at birth, inclusive of all gender identities). * Age 18 years or above at the time of signing the informed consent. * Body mass index (BMI) greater than or equal to (≥) 30.0 kilogram per square meter (kg/m\^2) at screening. * Participant must have a desire and be committed to lose at least 25 percentage (%) of their body weight from randomisation. Exclusion Criteria: * Known or suspected hypersensitivity to study intervention(s) or related products. * Treatment with any medication prescribed for the indication of obesity or weight management (e.g. glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues)) within 90 days before screening. * Glycated haemoglobin (HbA1c) ≥ 6.5% (48 Millimoles per mole \[mmol/mol\]) as measured by the central laboratory at screening. * History of type 1 or type 2 diabetes mellitus.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity

Contacts and locations

Locations

  • Cedar-Crosse Research Center

    Chicago, Illinois, 60607, United States

  • Chambliss Clinical Trials, LLC

    Montgomery, Alabama, 36106, United States

  • Clinical Res Collaborative

    Cumberland, Rhode Island, 02864, United States

  • Clinical Research Associates

    Nashville, Tennessee, 37203, United States

  • Encore Medical Research LLC

    Hollywood, Florida, 33024, United States

  • Endo And Metab Cons

    Rockville, Maryland, 20852, United States

  • FDRC

    Costa Mesa, California, 92627, United States

  • Family Practice Center of Wadsworth Inc.

    Wadsworth, Ohio, 44281-9236, United States

  • Great Lakes Clinical Trials

    Chicago, Illinois, 60640, United States

  • Great Lakes Medical Research

    Westfield, New York, 14787, United States

  • Holston Medical Group

    Kingsport, Tennessee, 37660, United States

  • Holston Medical Group_Bristol

    Bristol, Tennessee, 37620, United States

  • Isis Clinical Res. Ctr P.S.C.

    Guaynabo, 00968, Puerto Rico

  • KDCILM, LLC & Accellacare US, Inc.

    Wilmington, North Carolina, 28401, United States

  • L-MARC Research Center

    Louisville, Kentucky, 40213, United States

  • Los Angeles Institute for Metabolic Research

    Los Angeles, California, 90015, United States

  • Midwest Inst For Clin Res

    Indianapolis, Indiana, 46260, United States

  • National Clin Res Inc.

    Richmond, Virginia, 23294, United States

  • Pinnacle Clinical Research

    San Antonio, Texas, 78222, United States

  • PlanIt Research, PLLC

    Houston, Texas, 77079, United States

  • Rainier Clin Res Ctr Inc

    Renton, Washington, 98057, United States

  • South Broward Research LLC

    Miramar, Florida, 33027, United States

  • StudyMetrix Research LLC

    City of Saint Peters, Missouri, 63303, United States

  • UPA Ctr Weight and Eating Dis

    Philadelphia, Pennsylvania, 19104, United States

  • West Orange Endocrinology

    Ocoee, Florida, 34761, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.